A Global Early Empirical Therapy Randomized Study Design for Ivermectin in SARS-CoV-2 Infection

摘要

The review by Pierre et al1 has given a better clarity on data on ivermectin in COVID-19. However, as we know, a well-designed large-sample randomized trial is the way forward to confirm the precise effectiveness of ivermectin or lack if it. Present randomized studies have enrolled participants after confirming SARS-CoV-2 infection by polymerase chain reaction or the antigen test of nasopharyngeal or oropharyngeal swab.